Humanigen presents promising new hematologic data from PREACH-M trial for chronic myelomonocytic leukemia treatment at the 2023 European Hematology Association Congress
- Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months ...